Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel treatments for metabolic dysfunction‑associated steatohepatitis (MASH), formerly known as NASH.
It is the developer of the first FDA‑approved therapy for adults with moderate to advanced liver fibrosis.
Address: 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428
Phone: (267) 327‑4445
-
Fort Washington’s Madrigal Pharmaceuticals Completes Merger with Synta, Creates Leader in Field
Fort Washington’s Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the…
-
Fort Washington’s Madrigal Pharmaceuticals Procures $3.4 Million in Debt Financing
Fort Washington’s Madrigal Pharmaceuticals has procured $3.4 million in debt financing, according to a filing with the Securities and Exchange…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
